Polycystic Ovary Syndrome (PCOS) has been renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS) in the hope to better inform people and give more women support for the condition.

PMOS affects one in eight women and about 170 million women worldwide. The Lancet recently published information about the change and the hope is to improve understanding and help with treatment and diagnosis.

Symptoms can include; irregular periods, infertility, excess androgen effects (high level of male hormones which cause unwanted hair on the face, chest and back), skin and hair loss. PMOS can also be the cause of weight changes, insulin resistance (leading to increased hunger and fatigue), skin discoloration and skin tags. There can also be a link with low sex drive, fatigue and brain fog and finally mood changes.

The new name is welcomed as it is said to reflect the true nature of the condition. The original name suggested that the condition was limited to cysts in women’s ovaries but actually the condition heavily impacts the metabolism and the way the body produces energy. The new name raises awareness of the variety of symptoms that are linked to the condition which may help to inform, diagnose and treat more women who are suffering.

https://www.theguardian.com/so...

1. Why was PCOS renamed to PMOS?

2. How was the decision to change the name made?

3. What benefits are expected from the new name PMOS?